Fractyl Health, Inc. Common Stock (GUTS) Research

Fractyl Health, Inc. is a biopharmaceutical firm dedicated to advancing treatments for type 2 diabetes (T2D) and obesity. Among its offerings is the Revita DMR System (Revita), an outpatient procedure engineered to provide lasting modification of duodenal dysfunction. This condition often arises from diets high in fat and sugar, playing a role in the onset of T2D and obesity in individuals. Fractyl Health is also pioneering Rejuva, an innovative gene therapy platform utilizing a viral delivery system directly to the pancreas. Rejuva's objective is to achieve long-term remission from T2D and obesity by fundamentally altering metabolic hormone function within patients' pancreatic islet cells. Incorporated in 2010, the company, formerly known as Fractyl Laboratories Inc., officially became Fractyl Health, Inc. on June 9, 2021. Its operations are headquartered in Lexington, Massachusetts.

Market snapshot

Symbol
GUTS
Price
$0.86
Day change
+0.98%
Market cap
$62.0M
P/E ratio
-0.60x
52-week range
0.377-2.445
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$5.00

Peer companies

  • Adverum Biotechnologies, Inc. (ADVM)
  • ALX Oncology Holdings Inc. (ALXO)
  • Artiva Biotherapeutics, Inc. (ARTV)
  • aTyr Pharma, Inc. (ATYR)
  • Biomea Fusion, Inc. (BMEA)
  • Precision BioSciences, Inc. (DTIL)
  • Metagenomi, Inc. Common Stock (MGX)
  • Quince Therapeutics, Inc. (QNCX)

Recent insider activity

  • Royan Ajay — P-Purchase (23000 shares) on 2026-06-12
  • BRADLEY WILLIAM — P-Purchase (68493 shares) on 2026-06-10
  • BRADLEY WILLIAM — A-Award (22500 shares) on 2026-06-10
  • Conaway Samuel — A-Award (22500 shares) on 2026-06-10
  • Royan Ajay — A-Award (22500 shares) on 2026-06-10

Open Fractyl Health, Inc. Common Stock (GUTS) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.